(HealthDay News) – For patients with benign radiologic-pathologic concordant minimally invasive breast biopsy, interval imaging performed after <12 months has a low yield and high cost for detection of breast cancer, according to research presented at the annual meeting of the American Society for Breast Surgeons, held from May 1–5 in Chicago.

Demitra Manjoros, MD, from Bryn Mawr Hospital in Pennsylvania, and colleagues conducted a retrospective chart review involving 689 patients who underwent image-guided breast biopsy at the Comprehensive Breast Center between January and December 2010. Interval imaging was obtained <12 months after benign biopsy for 337 radiologic-pathologic concordant patients.

The researchers found that, for 95.9% of the concordant patients, interval imaging at <12 months was benign with Breast Imaging-Reporting and Data System (BI-RADS) 1, 2, or 3. A further 1.2% (two patients) received BI-RADS 0 and were deemed benign after further imaging. BI-RADS 4 was identified in five patients (3%), three at the original biopsy site and two at a distant site. Only one breast cancer was identified, representing 0.6% of all those concordant patients who underwent interval imaging. Detecting a missed cancer with interval imaging following benign radiologic-pathologic concordant minimally invasive biopsy cost an estimated $192,745.

“Interval imaging performed <12 months after benign radiologic-pathologic concordant breast biopsy had a low yield for the detection of breast cancer (0.6%) and resulted in increased health care costs,” the authors write. “These data support the policy for discontinuation of interval imaging <12 months after benign radiologic-pathologic concordant biopsy.”

More Information